Europe Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
Europe anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
Europe anti-vascular endothelial growth factor therapeutics market highlights
- The Europe anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 3,957.4 million in 2024.
- The market is expected to grow at a CAGR of -4.2% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Eylea is the most lucrative product segment registering the fastest growth during the forecast period.
Europe data book summary
| Market revenue in 2024 | USD 3,957.4 million |
| Market revenue in 2030 | USD 3,066.8 million |
| Growth rate | -4.2% (CAGR from 2024 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Eylea |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.2% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 9,124.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the Europe anti-vascular endothelial growth factor therapeutics market based on eylea covering the revenue growth of each sub-segment from 2018 to 2030.
Growing disease burden of ophthalmic diseases in the region and increasing investments for development of treatment options are expected to drive the anti-VEGF therapeutics market in the region. Prevalence and incidence of indications, such as AMD and diabetic retinopathies, are reported to be high in the region, which can support market growth.
Currently, there are various options available for the treatment of these diseases. However, anti-VEGF therapeutics are the first choice of treatment. According to a survey, around 61% of respondents in Europe prefer Eylea for the treatment of diabetic retinopathies and DME.
Healthcare in Europe is universal, with coverage available for all approved uses. On the contrary, reimbursement for off-label drug use differs across Europe in accordance with the existence of legislation permitting off-label use.
Reasons to subscribe to Europe anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe anti-vascular endothelial growth factor therapeutics market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
